Seeking Alpha
Editor's notes: NVDQ's cost and complication-reducing diagnostic technology - deemed "essential" by some surgeons - makes it one of the few remaining growth stories in med-tech. Sector expert Stephen Simpson sees 40% upside.

There aren't a lot of great med-tech growth stories these days, and many of those are already quite expensive. Novadaq Technologies (NVDQ) is hardly cheap at almost 22 times sales, but this company is very early in its product launch life and could see revenue grow from about $25 million over the trailing 12 months to perhaps $1 billion down the road.

With an affordable, safe, easy-to-use diagnostic system that delivers very real benefits in terms of lower complication rates and costs, Novadaq has an impressive opportunity as well as strong partners like LifeCell and Intuitive Surgical (ISRG) to help them realize those opportunities. I think it's relatively easy to argue that Novadaq is...

Only subscribers can access this article, which is part of the PRO research library covering 3,759 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: